Press Releases Items Per Page 102550 Year None2018201720162015201420132012201120102007 09.01.15 Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals as SVP and Chief Development Officer 08.26.15 Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab 08.24.15 Syndax Raises $80 Million in Series C Financing 06.15.15 Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer 03.31.15 Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma 03.12.15 Syndax to Participate in Two Upcoming Conferences 02.05.15 Syndax to Present at 2015 BIO CEO & Investor Conference 01.08.15 Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea 07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models 06.30.14 First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax's Entinostat 05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting 03.28.14 Syndax Files Registration Statement for Proposed Initial Public Offering Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
09.01.15 Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals as SVP and Chief Development Officer
08.26.15 Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab
06.15.15 Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer
03.31.15 Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
01.08.15 Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea
07.30.14 Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models
05.27.14 Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology(ASCO) Annual Meeting
